Biogen Inc

BIIB remains in a Stage 2 advancing medium-term regime within a longer-term downtrend supported by rising EMAs, but short-term sideways action and overbought conditions warrant patience. Medium-term bias is bullish, but price is extended above the EMAs. Short-term execution readiness is neutral; we will stalk for a pullback into the rising 9 and 21 EMA support zone for higher-probability entry.

• ↑Q1 2026 revenue $2.5B (+2% YoY) and GAAP diluted EPS $2.15 (+31% YoY)
• ↑Growth products (Lekembi, Zerzuve) delivered $851M revenue with 80% treatment persistence at 18 months
• ↓MS portfolio revenue declined 11% YoY due to generic competition, notably in Europe